Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents (Q63681898)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Francois Madore

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Louise M Moist

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Rob N Foley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Brendan J Barrett

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Colin T White

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Scott W Klarenbach

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Bruce F Culleton

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Braden J Manns

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Canadian Society of Nephrology

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

Kidney International. Supplement

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

74

0 references

page(s)

S12-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients.

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Epoetin-induced autoimmune pure red cell aplasia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Hospital-acquired infections related to contaminated substances

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Prospective evaluation of an anemia treatment algorithm in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.270

7 January 2021

Identifiers

DOI

10.1038/KI.2008.270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18668116%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference